Loading cancer entity…
Loading cancer entity…
Clinical trials
115 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03316573 | Pembrolizumab in Neoplasms or Lymphomas | suspended | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05028621 | Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease | suspended | N/A | 135 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
Showing 1–2 of 2 studies
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials